SCHEMBL4229394

SCHEMBL4229394

Cc1c(-c2ccccc2)nc2c(F)cccc2c1C(=O)NNc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 6/20 0.52
DHODH Q02127 3/20 0.50
TSHR P16473 2/20 0.45
PDE10A Q9Y233 1/20 0.45
CYP2C9 P11712 2/20 0.45
PTGFR P43088 7/20 0.44
TP53 P04637 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
NFKB1 P19838 1/20 0.43
TACR2 P21452 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4230491 0.83 TACR3 (0.72) TACR3DHODHTSHRPDE10ACYP2C9
SCHEMBL4228780 0.83 DHODH (0.70) DHODHTSHRPDE10A
SCHEMBL4230098 0.82 TACR3 (0.55) TACR3DHODHTSHRPDE10ACYP2C9
SCHEMBL4239917 0.77 TACR3 (0.80) TACR3CYP3A4TACR2
SCHEMBL4722551 0.75 TACR3 (0.45) TACR3DHODHTSHRPDE10APTGFR
SCHEMBL23590311 0.75 DHODH (0.65) DHODHTSHRPDE10ATP53
SCHEMBL29617670 0.75 DHODH (0.65) DHODHTSHRPDE10ATP53
SCHEMBL4229867 0.74 PTGFR (0.60) TACR3PTGFR
SCHEMBL13806890 0.72 GAA (0.62) TSHRCYP2C9ALDH1A1CYP1A2CYP3A4
SCHEMBL15597972 0.72 GAA (0.57) TSHRCYP2C9ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054440-A1 Quinoline derivatives as neurokinin receptor antagonists CARLING WILLIAM ROBERT 2009-02-26 US disclosed
EP-1888530-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2008-02-20 EP disclosed
WO-2006120478-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054440-A1 Quinoline derivatives as neurokinin receptor antagonists TACR2, TACR3, NPY2R TACR3 2/4885DHODH 3852/4885TSHR 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.